BLINCYTO — Total revenues
Amgen BLINCYTO — Total revenues decreased by 95.2% to $415M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 94.9%, from $8.15B to $415M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration, expanded clinical indications, or higher patient demand for the therapy, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross sales generated from the specific biopharmaceutical product line within the oncol...
Peer comparison
Comparable to specific product-line revenue disclosures in other large-cap biotechnology or pharmaceutical companies, particularly those focused on oncology or specialty therapeutics.
amgn_segment_blincyto_total_revenuesHistorical Data
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.53B | $118M | $6.71B | $118M | $6.85B | $118M | $6.24B | $145.75M | $6.59B | $145.75M | $6.65B | $145.75M | $6.84B | $145.75M | $6.11B | $194M | $6.99B | $206M | $6.9B | $220M | $8.2B | $241M | $7.45B | $244M | $8.39B | $264M | $8.5B | $327M | $9.09B | $381M | $8.15B | $370M | $9.18B | $384M | $9.56B | $392M | $9.87B | $413M | $8.62B | $415M |
| QoQ Change | — | -98.2% | >999% | -98.2% | >999% | -98.3% | >999% | -97.7% | >999% | -97.8% | >999% | -97.8% | >999% | -97.9% | >999% | -96.8% | >999% | -97.1% | >999% | -96.8% | >999% | -97.1% | >999% | -96.7% | >999% | -96.9% | >999% | -96.2% | >999% | -95.8% | >999% | -95.5% | >999% | -95.8% | >999% | -95.9% | >999% | -95.8% | >999% | -95.2% |
| YoY Change | — | — | — | — | — | — | — | — | +1.0% | -97.8% | -0.8% | -97.8% | -0.1% | -97.9% | -2.1% | -96.9% | +5.9% | -96.9% | +3.8% | -96.7% | +19.8% | -96.5% | +22.0% | -96.0% | +20.1% | -96.2% | +23.2% | -95.3% | +10.9% | -95.4% | +9.4% | -95.0% | +9.4% | -95.4% | +12.4% | -95.4% | +8.6% | -95.5% | +5.8% | -94.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's blincyto — total revenues?
- Amgen (AMGN) reported blincyto — total revenues of $415M in Q1 2026.
- How has Amgen's blincyto — total revenues changed year-over-year?
- Amgen's blincyto — total revenues decreased by 94.9% year-over-year, from $8.15B to $415M.
- What does blincyto — total revenues mean?
- The total annual revenue generated from sales of the specific oncology drug product line.